BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Employees - 17,
CEO - Dr. Peter A. Altman Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 10.15M
Altman ZScore(max is 10): -113.22, Piotroski Score(max is 10): 3, Working Capital: $-2061000, Total Assets: $2166000, Retained Earnings: $-162833000, EBIT: -5726000, Total Liabilities: $3686000, Revenue: $-55000
AryaFin Target Price - $0.21 - Current Price $1.96 - Analyst Target Price $6.00
| Ticker | BCDA |
| Index | - |
| Curent Price | 1.96 |
| Change | -10.91% |
| Market Cap | 10.15M |
| Average Volume | 81.57K |
| Income | -8.39M |
| Sales | 0.00M |
| Book Value/Share | -0.32 |
| Cash/Share | 0.18 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 20 |
| Moving Avg 20days | -22.12% |
| Moving Avg 50days | -17.79% |
| Moving Avg 200days | -19.97% |
| Shares Outstanding | 4.68M |
| Earnings Date | May 14 AMC |
| Inst. Ownership | 4.75% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 10.68 |
| Price/FCF | - |
| Quick Ratio | 0.36 |
| Current Ratio | 0.36 |
| Debt/Equity | - |
| Return on Assets | -346.38% |
| Return on Equity | -737.89% |
| Return on Investment | - |
| Gross Margin | -14333.33% |
| Ops Margin | -281733.33% |
| Profit Margin | -279700.00% |
| RSI | 38.90 |
| BETA(β) | 0.80 |
| From 52week Low | 20.62% |
| From 52week High | -68.13% |
| EPS | -2.58 |
| EPS next Year | -1.00 |
| EPS next Qtr | -0.50 |
| EPS this Year | 58.62% |
| EPS next 5 Year | 31.06% |
| EPS past 5 Year | 40.58% |
| Sales past 5 Year | 80.21% |
| EPS Y/Y | 63.06% |
| Sales Y/Y | -99.36% |
| EPS Q/Q | 56.76% |
| Sales Q/Q | -100.00% |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.29 |
| Perf Week | -28.47% |
| Perf Month | 12.19% |
| Perf Quarter | -21.60% |
| Perf Year | -67.01% |
| Perf YTD | -10.09% |
| Target Price | 6.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer